NCT00886132View on ClinicalTrials.gov

A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Adenoid Cystic CarcinomaSalivary Gland Cancer
Interventions
DRUG

Sunitinib

37.5 mg taken orally, daily every 28-day cycles

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT00886132 - A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands | Biotech Hunter | Biotech Hunter